MARKET

SIGA

SIGA

SIGA Tech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.22
-0.10
-1.37%
After Hours: 7.22 0 0.00% 16:00 11/23 EST
OPEN
7.35
PREV CLOSE
7.32
HIGH
7.37
LOW
7.06
VOLUME
182.69K
TURNOVER
--
52 WEEK HIGH
8.10
52 WEEK LOW
3.960
MARKET CAP
558.82M
P/E (TTM)
17.88
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
SIGA Technologies Chief Scientific Officer to Participate at NCT Asia Virtual Conference on November 13, 2020
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis Hruby, Chief Scientific Officer, will participate in a panel discussion at the Non-Conventional Threats (NCT) Asia Virtual Conference. The panel discussion titled, “COVID-19: Insights on an Epidemic Outbreak” will take place at 12:00 p.m. Malaysia Time on Friday, November 13, 2020 with Dr. Hruby speaking as one member of the panel at the conference.“With the COVID-19 pandemic continuing its devastating global impact, preparedness for the possibility of future pandemics are of increasing importance for governments worldwide. We look forward to providing information about TPOXX in addressing a potential smallpox outbreak, which is far more lethal than COVID-19,” said Dr. Hruby.ABOUT SIGA TECHNOLOGIES, INC. and TPOXX®SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX® is a novel small-molecule drug and the US maintains a stockpile of 1.7 million courses in the Strategic National Stockpile under Project BioShield. The oral formulation of TPOXX® was approved by the FDA for the treatment of smallpox in 2018. The full label is here: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fce826ab-4d6a-4139-a2ee-a304a913a253. In September 2018, SIGA signed a contract potentially worth more than $600 million with BARDA for additional procurement and development related to both oral and intravenous formulations of TPOXX®. For more information about SIGA, please visit www.siga.com.About Smallpox1Smallpox is a contagious, disfiguring and often deadly disease that has affected humans for thousands of years. Naturally occurring smallpox was eradicated worldwide by 1980, the result of an unprecedented global immunization campaign. Samples of smallpox virus have been kept for research purposes. This has led to concerns that smallpox could someday be used as a biological warfare agent. A vaccine can prevent smallpox, but the risk of the current vaccine's side effects is too high to justify routine vaccination for people at low risk of exposure to the smallpox virus.FORWARD-LOOKING STATEMENTS This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the year ended December 31, 2019, and in other documents that SIGA has filed with the SEC. SIGA urges investors and security holders to read those documents free of charge at the SEC's web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements are current only as of the date on which such statements were made, and except for our ongoing obligations under the United States of America federal securities laws, we undertake no obligation to update publicly any forward-looking statements whether as a result of new information, future events, or otherwise.The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.Contacts: Investors David Carey 212-867-1768 david.carey@finnpartners.comMedia Stephanie Seiler 206-713-0124 stephanie.seiler@finnpartners.com______________________________________1 http://www.mayoclinic.org/diseases-conditions/smallpox/basics/definition/con-20022769
GlobeNewswire · 11/12 21:05
SIGA Technologies beats on revenue
SIGA Technologies (SIGA): Q3 GAAP EPS of $0.31.Revenue of $44.3M (+446.9% Y/Y) beats by $17.8M.Press Release
Seekingalpha · 11/05 21:50
SIGA Technologies Q3 EPS $0.31 Up From $(0.03) YoY, Sales $44.30M Up From $8.10M YoY
SIGA Technologies (NASDAQ:SIGA) reported quarterly earnings of $0.31 per share. This is a 1133.33 percent increase over losses of $(0.03) per share from the same period last year. The company reported $44.30 million in
Benzinga · 11/05 21:50
SIGA Technologies, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 5, 2020 / SIGA Technologies, Inc.
ACCESSWIRE · 11/05 19:30
If You Had Bought SIGA Technologies (NASDAQ:SIGA) Stock Five Years Ago, You Could Pocket A 658% Gain Today
Simply Wall St. · 10/15 15:23
Canadian government agency to procure smallpox drug from SIGA Tech
Public Health Agency of Canada ((PHAC)) has awarded a contract to SIGA Technologies (SIGA) to purchase up to 33,300 courses of smallpox med TPOXX (tecovirimat) within five years, with 3,700 courses to be
Seekingalpha · 10/08 13:16
Dr. Dennis Hruby Wins 2021 ASM Award for Applied and Biotechnological Research
NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis Hruby, SIGA’s Chief Scientific Officer, has been named a recipient of the 2021 American Society for
GlobeNewswire · 08/31 12:30
SIGA Technologies beats on revenue
SIGA Technologies (NASDAQ:SIGA): Q2 GAAP EPS of $0.26. Revenue of $40.3M (+933.3% Y/Y) beats by $13.8M. Shares +10.7% AH. Press Release
seekingalpha · 08/07 02:11
More
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SIGA. Analyze the recent business situations of SIGA Tech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Institutional Holdings
Institutions: 153
Institutional Holdings: 25.46M
% Owned: 32.89%
Shares Outstanding: 77.40M
TypeInstitutionsShares
Increased
30
1.33M
New
30
-149.43K
Decreased
32
1.85M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.87%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Director
Eric Rose
Chief Executive Officer/Director
Phillip Gomez
Chief Financial Officer/Executive Vice President/Secretary
Daniel Luckshire
Chief Administrative Officer/General Counsel
Robin Abrams
Vice President/Chief Scientific Officer
Dennis Hruby
Independent Director
James Antal
Independent Director
Thomas Constance
Independent Director
Julie Kane
Independent Director
Joseph Marshall
Independent Director
Michael Plansky
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SIGA
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on health security market. The Company’s lead product TPOXX is approved by the Unites States Food and Drug Administration (FDA) as a drug with an indication for treatment of smallpox. TPOXX is an oral formulation, which is also known as tecovirimat and ST-246. The Company is developing the intravenous (IV) formulation for patients who are unable to swallow oral capsules. It is also focused on developing post-exposure prophylaxis (PEP), liquid suspension pediatric formulation and ST-357. PEP regimens are designed to prevent infection in individuals who have known or exposure to an infectious agent but are not symptomatic. The Company is developing a second mechanism of action smallpox small molecule antiviral drug that has shown efficacy in animal models of the disease.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of SIGA Technologies, Inc. stock information, including NASDAQ:SIGA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SIGA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SIGA stock methods without spending real money on the virtual paper trading platform.